Gene:
MAP2K3
mitogen-activated protein kinase kinase 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  MAP kinase kinase 3; MAPK/ERK kinase 3; dual specificity mitogen activated protein kinase kinase 3
Alternate Symbols:  MAPKK3; MEK3; MKK3
PharmGKB Accession Id: PA30588

Details

Cytogenetic Location: chr17 : q11.2 - p11.2
GP mRNA Boundary: chr17 : 21187968 - 21218552
GP Gene Boundary: chr17 : 21177968 - 21221552
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Tacrolimus/Cyclosporine Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of tacrolimus and cyclosporine, as well as the candidate genes believed to interact with the two drugs.
  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

External Pathways

Links to non-PharmGKB pathways.

  1. Cellular roles of Anthrax toxin - (Pathway Interaction Database NCI-Nature Curated)
  2. fmlp induced chemokine gene expression in hmc-1 cells - (BioCarta via Pathway Interaction Database)
  3. gata3 participate in activating the th2 cytokine genes expression - (BioCarta via Pathway Interaction Database)
  4. human cytomegalovirus and map kinase pathways - (BioCarta via Pathway Interaction Database)
  5. IL12-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  6. keratinocyte differentiation - (BioCarta via Pathway Interaction Database)
  7. links between pyk2 and map kinases - (BioCarta via Pathway Interaction Database)
  8. mapkinase signaling pathway - (BioCarta via Pathway Interaction Database)
  9. nfkb activation by nontypeable hemophilus influenzae - (BioCarta via Pathway Interaction Database)
  10. p38 MAPK signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  11. Regulation of p38-alpha and p38-beta - (Pathway Interaction Database NCI-Nature Curated)
  12. signal transduction through il1r - (BioCarta via Pathway Interaction Database)
  13. Signaling events mediated by VEGFR1 and VEGFR2 - (Pathway Interaction Database NCI-Nature Curated)
  14. Signaling mediated by p38-gamma and p38-delta - (Pathway Interaction Database NCI-Nature Curated)
  15. the 41bb-dependent immune response - (BioCarta via Pathway Interaction Database)
  16. TNF receptor signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  17. tnf/stress related signaling - (BioCarta via Pathway Interaction Database)
  18. toll-like receptor pathway - (BioCarta via Pathway Interaction Database)
  19. Trk receptor signaling mediated by the MAPK pathway - (Pathway Interaction Database NCI-Nature Curated)

Curated Information ?

No related diseases are available

Publications related to MAP2K3: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997. Kroll J, et al. PubMed

LinkOuts

Entrez Gene:
5606
OMIM:
602315
UCSC Genome Browser:
NM_002756
RefSeq RNA:
NM_002756
NM_145109
RefSeq Protein:
NP_002747
NP_659731
RefSeq DNA:
AC_000149
NC_000017
NT_010718
NW_001838428
NW_921423
UniProtKB:
MP2K3_HUMAN (P46734)
Q6FI23_HUMAN (Q6FI23)
Ensembl:
ENSG00000034152
GenAtlas:
MAP2K3
GeneCard:
MAP2K3
MutDB:
MAP2K3
ALFRED:
LO218142S
HuGE:
MAP2K3
Comparative Toxicogenomics Database:
5606
ModBase:
P46734
HumanCyc Gene:
HS00498
HGNC:
6843

Common Searches